Introduction
For patients told they cannot have LASIK because of thin corneas or a prescription that is too high, EVO ICL frequently represents not just an alternative — but the preferred option. These are the precise clinical scenarios in which EVO ICL’s additive, corneal-tissue-sparing approach produces outcomes that laser correction simply cannot match.
High myopia and thin corneas are among the most common disqualifying factors in LASIK candidacy assessments. Together or individually, they describe a patient population that has historically had limited options: glasses, contact lenses, or — in the most extreme cases — refractive lens exchange (replacing the natural lens before cataract formation). EVO ICL offers a third path that corrects vision to the same high standard as LASIK, preserves the natural lens, avoids the cornea entirely, and in many cases delivers superior optical quality.
This page examines the specific clinical reasons why EVO ICL is particularly well-suited for patients with high prescriptions and thin corneas, what to expect from outcomes in these populations, and how to find surgeons with the experience to manage these more demanding cases.
To explore the full landscape of EVO ICL excellence and find surgeons recognized for their outcomes across challenging cases, visit the EVO ICL Awards hub.
Section 1: Why LASIK Falls Short for High Prescriptions and Thin Corneas
The Corneal Tissue Problem
LASIK corrects myopia by removing corneal tissue. The amount of tissue removed is proportional to the prescription being corrected — higher prescriptions require more ablation. For every diopter of myopia corrected, the laser removes approximately 15 to 17 microns of stromal tissue (a figure that varies by laser platform, optical zone size, and ablation algorithm).
A patient with -10.00 diopters of myopia might require 150 microns or more of stromal ablation. A standard adult cornea measures between 500 and 550 microns in total thickness. After accounting for the LASIK flap (typically 90 to 120 microns), the available stromal bed before ablation begins is already reduced to 380 to 460 microns. Surgeons must leave at least 250 to 300 microns of residual stromal bed after ablation to avoid structural compromise and the risk of corneal ectasia — a progressive thinning and steepening of the cornea that can cause severe and irreversible vision loss.
Do the arithmetic and the problem becomes clear: for many patients with high myopia, especially those with thinner-than-average corneas to begin with, there is simply not enough tissue to safely perform the ablation needed to correct their prescription. LASIK is not the right procedure, not because of regulatory convention, but because of physics and biology.
Optical Quality Limitations at High Corrections
Even in patients who have enough tissue to technically undergo LASIK at high prescriptions, the optical quality of the outcome may be inferior. High-prescription LASIK creates a treatment zone with a steeper transition from the ablated center to the peripheral cornea. This transition induces higher-order aberrations — particularly spherical aberration — that affect night vision quality, contrast sensitivity, and the crispness of vision in variable lighting conditions.
EVO ICL avoids this problem entirely. Because the correction is applied inside the eye at the level of the posterior chamber rather than at the corneal surface, the cornea’s natural optical properties are fully preserved. The optical quality of high-prescription EVO ICL outcomes consistently demonstrates lower induced aberrations than comparable LASIK treatments.
Section 2: EVO ICL Performance in High-Myopia Populations
Clinical Evidence for High Prescription Outcomes
Clinical studies evaluating EVO ICL in patients with moderate to high myopia (-6.00 diopters and above) consistently show outcomes that meet or exceed what LASIK achieves in lower prescription ranges. Key findings include:
- Visual acuity: The majority of high myopia EVO ICL patients achieve 20/20 or better uncorrected distance vision. Studies of patients with prescriptions above -10.00 diopters show remarkable rates of excellent visual acuity — results that would be difficult or impossible to replicate with laser correction at those magnitudes.
- Predictability: The deviation between achieved refraction and target refraction remains low even at high prescription levels, reflecting the precision of STAAR Surgical’s lens power calculation and manufacturing.
- Quality of vision: Patient-reported visual quality metrics — including night driving, contrast sensitivity, and overall visual satisfaction — tend to be high in EVO ICL populations and are not degraded by the magnitude of the correction, unlike high-prescription LASIK.
The Extended Treatable Range
EVO ICL’s FDA-approved treatment range extends to -20.00 diopters. This represents a level of myopia at which no other corneal refractive procedure can produce reliable, safe outcomes. For severely myopic patients who have lived their entire lives with extreme optical dependence on glasses or contacts, EVO ICL can be genuinely life-changing.
Even within the more moderate range of -8.00 to -12.00 diopters, EVO ICL often produces a quality of visual outcome that exceeds what patients with these prescriptions could achieve with LASIK, even if LASIK were technically feasible.
Thin Corneas Are Not a Limiting Factor
Because EVO ICL does not touch the cornea, corneal thickness is not a limiting factor in the procedure. A patient with a cornea measuring 430 microns — far too thin for safe LASIK — may be a straightforward EVO ICL candidate if their anterior chamber depth and endothelial cell count are adequate. The cornea’s structural integrity is never compromised.
For a complete overview of candidacy criteria including anterior chamber depth requirements, see EVO ICL Candidacy: Who Is a Good Candidate?.
Section 3: Special Considerations for High-Prescription Patients
Retinal Health Evaluation
High myopia is associated with elongated axial length — the eye is physically longer than normal. This elongation stretches the peripheral retinal tissue and increases the risk of lattice degeneration, retinal holes, and retinal detachment. These risks exist regardless of whether the patient undergoes any refractive surgery.
Before EVO ICL implantation in a high myope, comprehensive dilated fundus examination by an experienced ophthalmologist is essential. Pre-existing retinal pathology — particularly retinal tears or areas of lattice degeneration with concerning features — should be treated with prophylactic laser retinopexy before lens implantation.
High myopes should also understand that their annual eye examinations must include retinal evaluation for the rest of their lives. EVO ICL corrects the optical consequence of myopia; it does not alter the physical anatomy of the eye or reduce the retinal risk profile that comes with high axial length.
Sizing Precision in Large Prescriptions
High-prescription ICLs tend to have slightly different mechanical properties than moderate-prescription versions due to the optic geometry required to achieve the higher refractive power. Experienced surgeons who work regularly with high-prescription patients develop familiarity with the handling and positioning characteristics specific to these lenses. This accumulated tactile experience contributes to better vault outcomes.
Surgeons recognized through the EVO ICL Awards program frequently demonstrate high-prescription EVO ICL expertise as part of their case mix, giving them a level of experience that benefits patients with the most demanding prescriptions.
Managing Expectations Around Residual Correction
Very high myopia — above -15.00 diopters — can occasionally require a small residual prescription after EVO ICL that the lens alone cannot fully eliminate, depending on available lens powers. In these cases, surgeons may perform a minor LASIK enhancement or surface ablation treatment over the ICL to refine the residual correction. This combined approach — sometimes called bioptics — is a recognized and well-documented technique that allows patients with extremely high prescriptions to achieve excellent functional vision.
Section 4: What High-Prescription Patients Should Look For
Surgeon Experience With Demanding Cases
Not all EVO ICL surgeons see the same mix of prescriptions. A surgeon who primarily treats moderate myopia (-4.00 to -8.00) may have limited exposure to the technical nuances of high-prescription cases. When evaluating providers, specifically ask about their experience with prescriptions similar to yours.
Questions to ask:
- What is the highest prescription you have treated with EVO ICL?
- How many patients per year do you treat in the -10.00 to -20.00 diopter range?
- What is your approach to lens sizing in high-prescription cases — do you use anterior segment OCT or UBM in addition to WTW measurement?
- What is your protocol if a patient has borderline anterior chamber depth and a high prescription?
For guidance on evaluating surgeon qualifications more broadly, see EVO ICL Surgeon Credentials: What to Look For and How EVO ICL Surgeons Are Evaluated for Awards.
Retinal Screening Infrastructure
Practices that treat high myopes responsibly have either a retinal specialist on staff or a strong referral relationship with one. If a practice does not mention retinal evaluation as part of the pre-operative work-up for a patient with high myopia, this is a gap in their candidacy protocol.
Transparency About Bioptics
If your prescription is in the range where bioptics (ICL plus LASIK touch-up) may be discussed, make sure your surgeon is transparent about when they recommend this approach, what the second procedure involves, and what additional cost it carries. A surgeon who presents bioptics proactively as a possible component of your treatment plan is being honest and thorough; one who does not mention it when treating -16.00 diopters may be overpromising full correction without contingency.
For information on comparing EVO ICL to LASIK in moderate prescription ranges, see EVO ICL vs LASIK: Which Vision Correction Is Right for You?.
Frequently Asked Questions
Can EVO ICL fully correct a -15.00 diopter prescription? In most cases, yes. STAAR Surgical’s lens inventory covers the full range up to -20.00 diopters, and the majority of high myopia patients achieve excellent uncorrected vision without a secondary enhancement. Occasionally, a small residual correction requires fine-tuning with a surface ablation procedure. Your surgeon can review the available lens powers and advise whether a single-procedure outcome is realistic for your specific prescription.
I was told my corneas are too thin for LASIK. Am I automatically a candidate for EVO ICL? Thin corneas do not disqualify you from EVO ICL — in fact, they are often the primary reason patients are directed toward EVO ICL in the first place. However, you still need adequate anterior chamber depth and endothelial cell count. Schedule a comprehensive evaluation to confirm all the necessary criteria. See EVO ICL Candidacy: Who Is a Good Candidate? for the full list.
Does high myopia mean a higher risk of complications with EVO ICL? High myopia itself does not directly increase the risk of EVO ICL complications. However, the management of high myopes requires additional pre-operative steps (retinal evaluation) and post-operative vigilance (ongoing retinal monitoring). Complication rates for the ICL implantation procedure itself are not significantly higher in high myopes compared to moderate myopes when candidacy criteria are carefully applied.
Will I need to return to glasses after EVO ICL for a high prescription? Most patients with high myopia achieve excellent functional distance vision after EVO ICL without glasses. As presbyopia develops in the mid-forties, reading glasses become necessary for near work — this is an age-related change unrelated to the ICL. See EVO ICL Safety Profile and Clinical Results for long-term stability data.
Next Steps
For patients with high prescriptions or thin corneas who have been told LASIK is not an option, EVO ICL deserves thorough consideration. The clinical evidence is clear: this procedure can deliver excellent visual outcomes in precisely the populations that laser correction serves least well.
The EVO ICL Awards hub identifies surgeons with demonstrated expertise in EVO ICL across the full prescription spectrum, including high-prescription and complex cases. Use this resource to find a provider with the specific experience your situation requires.